Background

We are the dominant holder of intellectual property for biomedical applications of NPS.



During November 2014, Pulse Biosciences acquired ThelioPulse, Inc. (“TPI”), BioElectroMed Corp. (“BEM”), and NanoBlate Corp. (“NB”) to establish a single, consolidated entity combining the efforts of the major companies working on NPS into one technology and intellectual property platform. As a result of the acquisitions of TPI, BEM and NB, as well as the exclusive license agreements relating to NPS for biomedical applications, we believe that our company is the dominant holder of intellectual property for biomedical applications of NPS. The company owns or exclusively licenses for biomedical use a patent portfolio encompassing 67 domestic and foreign patents and patents pending. This patent portfolio covers pulse generator and electrode design, methods of applying pulsed electric fields for disease indications and stimulation of biological effects utilizing pulsed electric fields in various medical indications, including cardiology, oncology, dermatology, neurodegenerative disease and aesthetic applications.